Transforming Diagnostics Through Collaboration
EpitogenX aims to revolutionise diagnostics through innovative technology and deep collaboration with academic and clinical partners. With a strong foundation in AI-driven solutions, the company has developed cutting-edge diagnostic tools that are already demonstrating real-world impact.
Award winners
EpitogenX have been recognised for their achievements by winning the Scottish Knowledge Exchange ‘Powerful Partnership’ award and being shortlisted for the ‘Innovation Collaboration’ award at the Scottish Life Sciences Awards. The team continues to expand its reach and capabilities, driven by a passion for solving complex healthcare challenges.
Ayham and Abdo Alnabulsi co-founders at EpitogenX said:
“Winning the ‘Powerful Partnerships’ and being shortlisted for ‘Innovation Collaboration’ validates our collaborative approach, innovation, and dedication to tackling real clinical challenges. The Powerful Partnership award boosts team morale while enhancing our credibility and visibility in the diagnostics space—opening doors to new partnerships, investment, and growth opportunities. Most importantly, it affirms the real-world impact of our work.”
Company Journey
The company’s journey began with first building on expertise and experience in the diagnostic and technology sectors, strengthened by close collaboration with world-class scientists and clinicians at the University of Aberdeen and NHS Grampian.
The team identified key limitations that were hindering progress in diagnostics. These gaps often result in misdiagnoses or missed opportunities for early intervention, negatively affecting patient outcomes. The team recognised an urgent need for more accurate, efficient, and accessible diagnostic solutions.
They developed a groundbreaking diagnostic platform enhanced by AI. The technology was validated through proof-of-concept studies, notably in the areas of COVID-19 and Lyme disease, showcasing its ability to accurately detect difficult-to-diagnose conditions. The solution not only improves diagnostic speed and reliability but also holds promise for broader application across multiple disease areas.
What’s next for EpitogenX?
“Winning this award is a key milestone, but just the beginning. We’re leveraging this recognition to drive our mission of transforming Lyme disease diagnostics and improving early detection. We're in discussions with stakeholders to secure FDA approvals, scale production, and expand our premises and team. We’re also working with the University of Aberdeen to finalise our Type 1 diabetes screening test, with clinical validation underway. Beyond Lyme and diabetes, we’re repurposing for diagnostic applications. Our goal is to continue innovating to tackle complex healthcare challenges and improve patient outcomes.”
ONE has had a significant impact on our business
“ONE regular events, such as Bio Buzz and Life Sciences Leadership Team, provides valuable opportunities to connect with other life-science companies, academics, clinicians, legal experts, and aspiring scientists, fostering collaboration and idea exchange. Additionally, ONE’s workshops, training programmes and investor pitching opportunities—such as Scale Your Sales programme, PR and marketing workshops, pitching to international investors—have sharpened our business skills, helping us boost revenue and drive rapid growth. The ONE team has also been an invaluable resource, offering ongoing advice and support to navigate key challenges and strategic decisions.”
Pictured: EpitogenX alongside the winners at the Scottish Knowledge Exchange Awards in Edinburgh.
Our advice to other businesses striving for success:
“Our advice would be to stay focused on your mission, remain adaptable, and prioritise collaboration. Success doesn't come overnight, but by continuously innovating, learning from setbacks, and building strong partnerships, you can drive meaningful progress. Surround yourself with a passionate and talented team, and always keep the patient or end-user at the heart of everything you do. Persistence, coupled with a clear vision, is key.”